mRNA-1273

PreclinicalCompleted

0 views this week 0 watching

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Myocarditis, Pericarditis

Conditions

Myocarditis, Pericarditis

Trial Timeline

Mar 31, 2023 → Aug 31, 2024

NCT ID

NCT06113692

About mRNA-1273

mRNA-1273 is a preclinical stage product being developed by Moderna for Myocarditis, Pericarditis. The current trial status is completed. This product is registered under clinical trial identifier NCT06113692. Target conditions include Myocarditis, Pericarditis.

What happened to similar drugs?

0 of 1 similar drugs in Myocarditis, Pericarditis were approved

Approved (0) Terminated (0) Active (1)

🔄Abatacept plus + PlaceboBristol Myers SquibbPhase 3

Clinical Trials (14)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07266558	Approved	Recruiting	Nov 26, 2025	Jun 16, 2027	SARS-CoV-2
NCT06113692	Preclinical	Completed	Mar 31, 2023	Aug 31, 2024	Myocarditis, Pericarditis
NCT05894499	Preclinical	Completed	Nov 15, 2022	May 26, 2023	SARS-CoV-2
NCT05894590	Preclinical	Completed	Nov 15, 2022	Dec 20, 2023	SARS-CoV-2
NCT05894525	Preclinical	Completed	Nov 15, 2022	May 26, 2023	SARS-CoV-2
NCT05397223	Phase 1	Completed	May 24, 2022	Feb 27, 2026	SARS-CoV-2, Seasonal Influenza, Respiratory Syncytial Virus, Cytomegalovirus
NCT05366322	Preclinical	Completed	Sep 10, 2021	Feb 4, 2022	SARS-CoV-2
NCT04958304	Preclinical	Terminated	Sep 1, 2021	Sep 22, 2023	SARS-CoV-2
NCT04958954	Preclinical	Completed	Jul 7, 2021	Aug 31, 2022	SARS-CoV-2
NCT04860297	Phase 3	Completed	Apr 16, 2021	May 22, 2023	SARS-CoV-2
NCT04796896	Phase 3	Completed	Mar 15, 2021	Mar 15, 2024	SARS-CoV-2
NCT04649151	Phase 3	Completed	Dec 9, 2020	Jun 14, 2024	SARS-CoV-2
NCT04470427	Phase 3	Completed	Jul 27, 2020	Dec 29, 2022	SARS-CoV-2
NCT04405076	Phase 2	Completed	May 29, 2020	Oct 28, 2021	SARS-CoV-2

Competing Products

3 competing products in Myocarditis, Pericarditis

See all competitors

Product	Company	Stage	Hype Score
SPIKEVAX	Moderna	Preclinical	0
Abatacept plus + Placebo	Bristol Myers Squibb	Phase 3	47
Treatment with G-CSF (Granulocyte colony stimulating factor) + Placebo saline	Rafael Holdings	Phase 2	25